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Abstract:  
Patients with antiphospholipid syndrome (APS) present with clinical features of recurrent 
thrombosis and pregnancy morbidity and persistently test positive for the presence of 
antiphospholipid antibodies (aPL). At least one clinical (vascular thrombosis or pregnancy 
morbidity) and one lab-based (positive test result for lupus anticoagulant, anticardiolipin 
antibodies and/or anti-β2-glycoprotein 1 antibodies) criterion have to be met for a patient to be 
classified as having APS. Nevertheless, the clinical variety of APS encompasses additional signs and 
symptoms, potentially affecting any organ, that cannot be explained exclusively by a 
prothrombotic state. Those manifestations, also known as extra-criteria manifestations, include 
haematologic (thrombocytopenia and haemolytic anaemia), neurologic (chorea, myelitis and 
migraine) manifestations as well as the presence of livedo reticularis, nephropathy and valvular 
heart disease. The growing body of evidence describing the clinical aspect of the syndrome has 
been paralleled over the years by emerging research interest focusing on the development of 
novel biomarkers that might improve the diagnostic accuracy for APS when compared to the 
current aPL tests. This review will focus on the clinical utility of extra-criteria aPL 
specificities.Besides, the promising role of a new technology using particle based multi-analyte 
testing that supports aPL panel algorithm testing will be discussed. Diagnostic approaches to 
difficult cases, including real-world case studies investigatingthe diagnostic added value of extra 









1.1 Introduction - Filling the gaps in APS diagnosis  
 
The antiphospholipid syndrome (APS) is a unique form of acquired autoimmune thrombophilia 
initially described in 1980s [1], referring to individuals who presented with recurrent thrombosis 
(arterial and/or venous) and/or pregnancy complications and who tested persistently positive for 
antiphospholipid antibodies (aPL). 
The current aPL included in the laboratory classification criteria [2] are lupus anticoagulant (LA), 
anticardiolipin antibodies (aCL) and anti-β2-glycoprotein 1 (aB2GPI) antibodies. Most of the 
autoantibodies found in the patients' serum are directed against the plasma apolipoproteins that 
bind the phospholipids, especially β2-glycoprotein-1 and prothrombin. Since its first description, 
the number of antibodies that have been associated to APS is constantly increasing[3].  While the 
tests currently included in the classification criteriaare able to correctly detect the great majority 
of the cases, some patients at high clinical suspicion of APSmay be not identified. The diagnostic 
utility of tests non included in the criteria (so-called extra criteria aPL tests) is currently debated 
[4] and, among the others, the relevance of extra criteria aPL such as anti-
phosphatidylserine/prothrombin (aPS/PT) antibodies and IgA isotypes has been proposed as an 
additional tool to be considered when investigating a patient suspected of having APS, particularly 
in the absence of routine aPL[5,6], or as a part of risk assessment strategies [7]. 
The importance of early diagnosis is now a well-recognized notion in the management of many 
rheumatic diseases, and it is still an unmet need in patients with APS. Ideally, the prompt 
identification of aPL could modify the strategy of treatment, impacting on both pregnancy-related 
and thrombotic events management.  
Herewith, we aimto discuss the added diagnostic value of testing for extra criteria aPL. Besides, a 
special focus on the emerging role of particle-based multi-analyte technology(PMAT) that 
embraces aPL panel testing and profiling will be examined.  
 
2. New frontiers in aPL testing: The panel approach 
The advent of new diagnostic platforms combined with deep learning artificial intelligence 
constitutes a new frontier in aPL testing that holds the promise of closing serological gaps in 
autoantibody diagnostics. This has been demonstrated by recent studies showing the potential 
clinical utility of this profiling approach in rheumatoid arthritis an idiopathic inflammatory 
myopathy[8–11]. 
In recent years, a full automated digital system using PMAT has been developed which allows for 
the simultaneous detection of autoantibodies and proteins. More specifically, the APS reagents 
detect antibodies of IgG, IgA and IgM isotypes to CL, ß2GPI and PS/PT, resulting in a profile of 9 
different aPL tests. 
The analytes in the assays are created by covalently binding antigens to paramagnetic 
microparticles. Each analyte is associated with a discrete population of particles with a unique 
signature that allows for their classification by an optical module. The optical module is composed 
of two light-emitting diodes (LEDs) units set to different wavelengths and one charge-coupled 
device sensor.  One diode is used to classify the particles into discrete sets (populations) that are 
assigned to a specific analyte, this is achieved by shining light at a specific electromagnetic 
wavelength, while the second diode shines light at a different wavelength, selected specifically, to 
excite the fluorochromes present in the phychoerythrin conjugated to anti-human IgG, IgM or IgA 
detection antibodies.  
Multiple images are generated by the system in order to identify and count the three unique 
analyte particles, as well as determine the amount of conjugate on each particle. A fourth particle, 
coated with goat anti-human antibodies (IgG, IgM or IgA, depending on isotype), is present in the 
reagent as a control to detect that the patient serum sample and the conjugate have been added. 
The median fluorescent intensity (MFI) for each analyte is proportional to the concentration of 
conjugate bound to human IgG, IgM or IgA, which is proportional to the concentration of IgG, IgM 
or IgA bound to the corresponding particle population.   
Each analyte in the PMAT APS reagent is assigned a predefined lot specific master curve.  The 
analyte specific master curve is stored on the reagent’s cartridge radio frequency identification 
label. Based on results obtained by running calibrators (supplied separately), the system creates 
individual working curves used by the software to calculate fluorescent light units for each analyte 
from the MFI values obtained for each sample. 
Prior to use in the full automated digital instrument, the isotype-specific reagent cartridge, 
containing all required components, is prepared by piercing the sealed reagent tubes with the 
cartridge lid. Once place onboard, the instrument will automatically rehydrate the microparticles. 
A patient serum sample is pre-diluted by the instrument with sample buffer in a small disposable 
plastic cuvette. Small amounts of the diluted patient serum, the microparticles, and the assay 
buffer are all combined into a second cuvette, mixed, and then incubated for 9.5 minutes at 37ºC. 
The magnetized microparticles are washed repeatedly, before being transferred to the optical 
module for quantitation.  
 
3. Case Study: Added clinical value of the aPL panel approachin patients suspected for APS  
3.1 Patients selection 
We chart-reviewed patients with thrombotic events and/or pregnancy morbidity who tested 
persistently positive for at least one aPL (more than 2 occasions over a time ofmore than 12 
weeks) that presented at San Giovanni Bosco Hospital in the last 5 years. The study was 
performed in compliance with the Declaration of Helsinki.  
We enrolled 80 patients who met one of the following inclusion criteria:  
1) Fulfilled the diagnosis of APS defined as per Sydney criteria [2]. 
2) Patients with thrombosis and/or pregnancy morbidity and suspected APS not completely 
fulfilling the laboratory criteria [2], as follows: a) inconsistent previous LA positivity; and/or b) low-
medium titersaPL [defined as levels of aCL IgG/IgM or aβ2GPI IgG/IgM between 10-30 GPL/MPL]. 
Clinical and laboratory characteristics were retrospectively collected.  
 
3.2 Previous autoantibody detection and testing with PMATplatform 
The aPL routine testing at diagnosis included LA as well as aCLa, β2GPIand aPS/PT (IgG and IgM 
isotypes) antibodies. Venous blood was collected using a 21-gauge butterfly needle, with minimal 
venous stasis, into Vacutainer® tubes (BD, Plymouth, UK). Serum was collected after double 
centrifugation at ambient temperature (2000 g for 15 minutes) and stored in aliquots at -80 °C. 
The aCL and aß2GPI and aPS/PT(IgG and IgM) antibodieswere detected by commercial enzyme-
linked immunosorbent assay (ELISA) (QUANTA Lite®, Inova Diagnostics). Plasma samples were 
tested for the presence of LA according to the recommended criteria from the International 
Society on Thrombosis and Haemostasis (ISTH) Subcommittee on Lupus 
Anticoagulant/Phospholipid-Dependent Antibodies [12,13]. The samples were then tested with 
the Aptiva™, full automated digital system using PMAT, andAptiva™ APS reagents (Inova 
Diagnostics, San Diego, CA; under development and for research use only).  
 
3.3 Results  
A total of 80 patients were included for analysis. Seventy-four (92.5%) patients presented with 
previous thrombotic events, 6(7.5%) presented with previous history of pregnancy morbidity 
(fulfilling the clinical criteria for APS [2]). Four(5%) patients presented with both.  Further, 65 
(81.3%) patients fulfilled the diagnosis of thrombotic APS defined as per Sydney criteria [2] and 15 
(18.8%) patients did not completely fulfilling the laboratory criteria [2], as previously defined in 
the inclusion criteria of the study.  
When testing with the PMAT APS reagents, 70 patients (87.5%) tested positive for at least one aPL, 
as illustrated in Figure 1. Thirty-height (47.5%) patients tested positive for aCL IgG. The number of 
positive patients increased to 55 (68.8%) patients when testing for aβ2GPI and aCL IgG/M. 
Interestingly, the number of positive patients further increased to 59 (73.8%) and 69 (86.3%) when 
adding the IgA isotype for aCL and aβ2GPI antibodies as well as aPS/PT IgG/IgM antibodies, 
respectively. 
When limiting the analyses to the patients with thrombosis and/or pregnancy morbidity and 
suspected APS not completely fulfilling the laboratory criteria, 9/15(60.0%) were found positive for 
aPL when tested with PMAT(7/15 positive for aCL IgG/M and/or aβ2GPIIgG/M). Remarkably, two 
patients with thrombosis were positive for aPS/PT only (one patient with aPS/PT IgG and IgM, one 
patient withIgM alone).  
 
4. Discussion 
Careful evaluation of autoantibody assays for the detection of aPL is of utmost importance since 
some of these antibodies are included or being considered for APS classification criteria [2,3].  The 
markers are not only relevant for establishing the diagnosis, but also in the stratification into risk 
specific subsets [7]. 
The reliability of autoantibody measurements (i.e. reproducibility of the test) and the diagnostic 
accuracy (i.e. ability to identify patients at higher risk for a specific condition) are therefore crucial 
for optimum patient care and management. Historically, ELISA-based assays have been used to 
confirm and quantify the concentration of autoantibodies in patient samples. These 
measurements have traditionally been performed in specialized immunology laboratories. 
However, autoantibody testing is now commonplace with an increasing tendency towards more 
automated methods, in larger number of laboratories. As the number of testing increases, the 
number of available techniques for immunological testing is increasing as well.On the other hand, 
as medical intervention moves to disease prediction and a model of “intent to PREVENT”, 
diagnostics will need to include an early symptom/risk-based, as opposed to a disease-based 
approach. With the potential of simultaneously testing several analytes on a small sample size, 
newer diagnostic platforms based on multi-analyte technology has the potential to facilitate the 
shift to a personalized medicine approach.aPL testing mighttherefore undergo a paradigm shift, 
moving from being solely a diagnostic marker to be consider a biomarker to help in different 
clinical settings, including disease prediction and prevention; early and accurate diagnosis; and 
effective and timely treatment. Here we presented a case study to provide evidence to support 
the use of PMATto identify patients suspected for APS. Which is most interesting of our 
preliminary findings is that 60% of patients with thrombosis and/or pregnancy morbidity and 
suspected APS not completely fulfilling the laboratory criteria were found positive for at least one 
aPL when tested with PMAT. More intriguingly, 2/15 (13.3%) of them were positive only for 
aPS/PT.  
From this perspective, our study helps to provide some further evidenceaiming to address the 
question: “Should aPS/PT be incorporated into the routine serological tests in the diagnosis of 
APS?” Some considerations are worth mentioning when addressing this point.  
Firstly, aPS/PT covers a significant proportion of patients clinically suspected for having APS but 
negative LA, aCL and aβ2GPI, and the combination of aPS/PT with traditional aPL further enhances 
the diagnostic power. Secondly, the introduction of aPS/PT further strengthens risk stratification in 
patients with APS. Thirdly, when the 2006 international consensus statement[2]was proposed, the 
detection of aPS/PT was mainly based on in-house ELISA, resulting in large variability among 
different studies.Over the past 10 years, the performance of ELISA-based systems for detection of 
aPS/PT has substantially improved, and commercially available assays with improved sensitivity 
and specificity have been evaluated in many studies[14]. Data coming from 2 available systematic 
reviews[15,16] involving about 10.000subjects have shown a strong association between aPS/PT 
and the clinical manifestations of APS. With the available level of evidence, aPS/PT testing can be 
considered as a robust test applicable in the management of patients suspected for APS, also 
beyond the research settings. One significant limitation of our study is that we did not include a 
control population that would allow for assessing the specificity. However, the specificity of the 
assays has previously been established[17].  
While additional studies based on larger cohorts are needed to fully assess the assay performance 
on the novel PMAT system for the measurement of autoantibodies in APS, the approach PMAT 
offers for detecting a spectrum of antibodies in patients suspected for APS represents a leading 
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Figure 1. Added progressive percentage of patients positive for antiphospholipid antibodies 
 
 
Figure 1. Added progressive percentage of patients positive for antiphospholipid antibodies 
(divided for isotypes)  
 
